Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

It is widely accepted that sugar and foods high in sugar will make a child or young person hyperactive and extremely energetic. However, research conducted over the last 20 years has shown that sugar ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

Patients with knee osteoarthritis who received metformin demonstrated significant reductions in knee pain and increased ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

An oral melanocortin-4 receptor agonist conferred significant BMI reductions among adolescents and adults with hypothalamic ...

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

A motion sickness drug that treats severe depression in hours? Discover how scopolamine may revolutionize mental health ...

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...